1. Abstract
Sex steroid hormones influence hypothalamic micro- and macrostructure in humans and animal models. Neuroimaging studies have suggested that estrogen and anti-androgen treatment decreases volumes of multiple cortical and subcortical brain areas in transgender individuals, including total hypothalamus volume. Here, we aim to further explore potential effects of gender-affirming hormone treatment (GHT) in transgender individuals on hypothalamic volume by providing additional information on hypothalamic subfields.
38 transgender men (TM) and 15 transgender women (TW), with gender dysphoria (DSM-5), as well as 32 cisgender women (CW) and 21 cisgender men (CM) underwent two magnetic resonance imaging (MRI) measurements with an interval of at least four months (median interval TM= 134.5 days (interquartile range (IQR): 126-152.25); TW= 149 days (IQR: 126-178.5); CW= 147 days (IQR: 139.75-170.5); CM= 146 days (IQR: 132-247)) between both sessions. In transgender individuals GHT, consisting of estrogen and anti-androgen treatment in TW and testosterone treatment in TM, was initiated directly after the first measurement. To assess how GHT interacts with hypothalamic structures, the hypothalamus and its subunits were segmented using FreeSurfer. Subject group x time interaction effects were evaluated using repeated measures ANCOVA models. The Bonferroni method was used to correct for multiple comparisons.
Significant decreases of total hypothalamic volume and associated subunits were detected in TW after estrogen and anti-androgen treatment compared to cisgender groups. Effects were found in the total hypothalamus volume (pcorr= 0.001), the left and right hypothalamus (pcorr= 0.002), the inferior tubular subunit bilaterally (right: pcorr= 0.001; left: pcorr= 0.001), the left superior tubular subunit (pcorr= 0.003) the right anterior inferior subunit (pcorr= 0.002), as well as the right anterior superior subunit (pcorr= 0.0002) of the hypothalamus.
Here, we observed significant volumetric effects on the adult human hypothalamus after an interval of at least four months of estrogen and anti-androgen treatment in TW and added knowledge on associated subfields. Further studies investigating influences of sex steroid hormones on brain structure and functional connections are still needed.
Competing Interest Statement
Without relevance to this work, R. Lanzenberger received travel grants/financial compensation for conference talks within the last three years from Bruker BioSpin MR and Heel. He was a consultant for Ono Pharmaceutical. He received funding for clinical research using PET/MR from Siemens Healthcare and is involved in the start-up company BM Health GmbH since 2019 as a shareholder.
Funding Statement
This research was funded in whole, or in part, by the Austrian Science Fund (FWF) [KLI504 and P23021, PI: Lanzenberger Rupert]. For the purpose of open access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission. M.B. Reed and M. Kloebl received funding from a DOC Fellowship, Austrian Academy of Science. This research was supported by the grant 'Interdisciplinary translational brain research cluster (ITHC) with highfield MR' from the Federal Ministry of Science, Research and Economy (BMWFW), Austria. M.E. Konadu received support by the Austrian National Union of Students for conducting this analysis.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of the Medical University of Vienna gave ethical approval for this work (EK number: 1104/2015 and 644/2010)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
For reasons of data protection, the data is available on reasonable request from the corresponding author.
